Other clinical studies are evaluating the efficacy of everolimus-tamoxifen (a SERM) co-treatment in postmenopausal women with locally advanced/metastatic, HR-positive, HER2-negative, AI-resistant breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.